Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B - 12/05/18
Doi : 10.1016/j.jaad.2018.02.023
Deep Joshipura, MD, Abdulaziz Alomran, MD, Pedro Zancanaro, MD, David Rosmarin, MD ⁎ 
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts
∗Correspondence to: David Rosmarin, MD, Tufts Medical Center, 800 Washington St, no. 114, Boston, MA 02111.Tufts Medical Center800 Washington St, no. 114BostonMA02111
| Funding sources: None. |
|
| Conflicts of interest: Dr Rosmarin has served on advisory boards or is a consultant to Pfizer, Eli Lilly, Abbvie, Janssen, Regeneron, Sanofi, Celgene, and Novartis. Dr Rosmarin also serves as an investigator for Incyte. Other authors do not have disclosures to report. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 78 - N° 6
P. 1205 - juin 2018 Retour au numéro
Article précédent
- Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review
- Ladan Afifi, Isabelle M. Sanchez, Matthew M. Wallace, Sara F. Braswell, Alex G. Ortega-Loayza, Kanade Shinkai
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Elana Putterman, Leslie Castelo-Soccio
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?